Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Unknown 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2

Conditions

Nasopharyngeal Carcinoma 18Squamous Cell Carcinoma of Head and Neck 11Head and Neck Neoplasms 9Recurrence 2Nasopharyngeal Neoplasms 2Pathologic Complete Response 1Oropharyngeal Neoplasms 1Neoplasm Metastasis 1Nasopharyngeal Diseases 1Hypopharyngeal Neoplasms 1Carcinoma 1

Interventions

Cisplatin 41Gemcitabine 25Radiotherapy, Intensity-Modulated 15Fluorouracil 15Radiotherapy 12Docetaxel 10pembrolizumab 8Paclitaxel 8Carboplatin 8Capecitabine 7Oxaliplatin 5toripalimab 4spartalizumab 4Surveys and Questionnaires 4Bevacizumab 4camrelizumab 3Nivolumab 3Induction Chemotherapy 3Immunohistochemistry 3Endostatins 3Counseling 3Cetuximab 3Acupuncture Therapy 3tislelizumab 2sintilimab 2nimotuzumab 2endostar protein 2apatinib 2Taxes 2Psychiatric Rehabilitation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Nasopharyngeal Neoplasms × nimotuzumab × Head & Neck × Clear all
NCT03837808 2022-11-07

Radiotherapy Plus Concurrent Nimotuzumab or Cisplatin in Stage II-III Nasopharyngeal Carcinoma

Sun Yat-sen University

Phase 3 Unknown
384 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Head and Neck Neoplasms, Nasopharyngeal Diseases, Nasopharyngeal Neoplasms

NCT01074021 2015-10-30

Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer

Biotech Pharmaceutical Co., Ltd.

Phase 3 Unknown
480 enrolled
Head & Neck

Nasopharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡